Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Employees - 21, CEO - Mr. Stephen Anthony Stamp, Sector - Healthcare, Country - GB, Market Cap - 0.85M

Altman ZScore(max is 10): -17.89, Piotroski Score(max is 10): 1, Working Capital: $4043000, Total Assets: $13968000, Retained Earnings: $-147881000, EBIT: -14621000, Total Liabilities: $5241000, Revenue: $612000

- Current Price $1.47 - Analyst Target Price $18.00